Venrock Healthcare Capital Partners Iii, L.p. - Net Worth and Insider Trading

Venrock Healthcare Capital Partners Iii, L.p. Net Worth

The estimated net worth of Venrock Healthcare Capital Partners Iii, L.p. is at least $228 Million dollars as of 2024-04-27. Venrock Healthcare Capital Partners Iii, L.p. is the 10% Owner of Constellation Pharmaceuticals Inc and owns about 4,016,873 shares of Constellation Pharmaceuticals Inc (CNST) stock worth over $137 Million. Venrock Healthcare Capital Partners Iii, L.p. is the 10% Owner of KalVista Pharmaceuticals Inc and owns about 4,824,731 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $52 Million. Venrock Healthcare Capital Partners Iii, L.p. is also the 10% Owner of Altimmune Inc and owns about 4,500,000 shares of Altimmune Inc (ALT) stock worth over $33 Million. Besides these, Venrock Healthcare Capital Partners Iii, L.p. also holds Cogent Biosciences Inc (COGT) . Details can be seen in Venrock Healthcare Capital Partners Iii, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Venrock Healthcare Capital Partners Iii, L.p. has not made any transactions after 2024-02-08 and currently still holds the listed stock(s).

Transaction Summary of Venrock Healthcare Capital Partners Iii, L.p.

To

Venrock Healthcare Capital Partners Iii, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Venrock Healthcare Capital Partners Iii, L.p. owns 7 companies in total, including Cogent Biosciences Inc (COGT) , Altimmune Inc (ALT) , and Constellation Pharmaceuticals Inc (CNST) among others .

Click here to see the complete history of Venrock Healthcare Capital Partners Iii, L.p.’s form 4 insider trades.

Insider Ownership Summary of Venrock Healthcare Capital Partners Iii, L.p.

Ticker Comapny Transaction Date Type of Owner
COGT Cogent Biosciences Inc 2020-08-18 10 percent owner
ALT Altimmune Inc 2021-02-25 10 percent owner
CNST Constellation Pharmaceuticals Inc 2019-12-13 10 percent owner
BLPH Bellerophon Therapeutics Inc 2018-09-05 10 percent owner
KALV KalVista Pharmaceuticals Inc 2024-02-08 10 percent owner
TCDAQ Tricida Inc 2022-06-01 10 percent owner
VTGN Vistagen Therapeutics Inc 2022-04-06 10 percent owner

Venrock Healthcare Capital Partners Iii, L.p. Latest Holdings Summary

Venrock Healthcare Capital Partners Iii, L.p. currently owns a total of 4 stocks. Among these stocks, Venrock Healthcare Capital Partners Iii, L.p. owns 4,016,873 shares of Constellation Pharmaceuticals Inc (CNST) as of December 13, 2019, with a value of $137 Million and a weighting of 59.94%. Venrock Healthcare Capital Partners Iii, L.p. owns 4,824,731 shares of KalVista Pharmaceuticals Inc (KALV) as of February 8, 2024, with a value of $52 Million and a weighting of 22.83%. Venrock Healthcare Capital Partners Iii, L.p. also owns 4,500,000 shares of Altimmune Inc (ALT) as of June 15, 2020, with a value of $33 Million and a weighting of 14.34%. The other 1 stocks Cogent Biosciences Inc (COGT) have a combined weighting of 2.88% among all his current holdings.

Latest Holdings of Venrock Healthcare Capital Partners Iii, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CNST Constellation Pharmaceuticals Inc 2019-12-13 4,016,873 33.99 136,533,513
KALV KalVista Pharmaceuticals Inc 2024-02-08 4,824,731 10.78 52,010,600
ALT Altimmune Inc 2020-06-15 4,500,000 7.26 32,670,000
COGT Cogent Biosciences Inc 2020-08-18 1,088,818 6.02 6,554,684

Holding Weightings of Venrock Healthcare Capital Partners Iii, L.p.


Venrock Healthcare Capital Partners Iii, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Venrock Healthcare Capital Partners Iii, L.p. has made a total of 1 transactions in Constellation Pharmaceuticals Inc (CNST) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Constellation Pharmaceuticals Inc is the acquisition of 400,000 shares on December 13, 2019, which cost Venrock Healthcare Capital Partners Iii, L.p. around $14 Million.

According to the SEC Form 4 filings, Venrock Healthcare Capital Partners Iii, L.p. has made a total of 9 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years, including 9 buys and 0 sells. The most-recent trade in KalVista Pharmaceuticals Inc is the acquisition of 86,048 shares on February 8, 2024, which cost Venrock Healthcare Capital Partners Iii, L.p. around $1 Million.

According to the SEC Form 4 filings, Venrock Healthcare Capital Partners Iii, L.p. has made a total of 2 transactions in Altimmune Inc (ALT) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Altimmune Inc is the acquisition of 1,500,000 shares on June 15, 2020, which cost Venrock Healthcare Capital Partners Iii, L.p. around $11 Million.

More details on Venrock Healthcare Capital Partners Iii, L.p.'s insider transactions can be found in the Insider Trading History of Venrock Healthcare Capital Partners Iii, L.p. table.

Insider Trading History of Venrock Healthcare Capital Partners Iii, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Venrock Healthcare Capital Partners Iii, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Venrock Healthcare Capital Partners Iii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Venrock Healthcare Capital Partners Iii, L.p. is 8.5%. GuruFocus also compares Venrock Healthcare Capital Partners Iii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Venrock Healthcare Capital Partners Iii, L.p. within 3 months outperforms 2 times out of 11 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Venrock Healthcare Capital Partners Iii, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Venrock Healthcare Capital Partners Iii, L.p.

Average Return

22.87%

Average return per transaction

Outperforming Transactions

50%

2 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 29.12 8.5 16.13 22.87 0.3 -12.36
Relative Return to S&P 500(%) 25.77 3.34 3.13 -7.8 -13.29 -23.5

Venrock Healthcare Capital Partners Iii, L.p. Ownership Network

Ownership Network List of Venrock Healthcare Capital Partners Iii, L.p.

No Data

Ownership Network Relation of Venrock Healthcare Capital Partners Iii, L.p.


Venrock Healthcare Capital Partners Iii, L.p. Owned Company Details

What does Cogent Biosciences Inc do?

Who are the key executives at Cogent Biosciences Inc?

Venrock Healthcare Capital Partners Iii, L.p. is the 10 percent owner of Cogent Biosciences Inc. Other key executives at Cogent Biosciences Inc include 10 percent owner & other: See Remarks Fairmount Funds Management Llc , Chief Legal Officer Evan Kearns , and Chief Financial Officer John L. Green .

Cogent Biosciences Inc (COGT) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Iii, L.p. made no insider transaction in Cogent Biosciences Inc (COGT). Other recent insider transactions involving Cogent Biosciences Inc (COGT) include a net purchase of 800,000 shares made by Fairmount Funds Management Llc ,

In summary, during the past 3 months, insiders sold 0 shares of Cogent Biosciences Inc (COGT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cogent Biosciences Inc (COGT) were sold and 800,000 shares were bought by its insiders, resulting in a net purchase of 800,000 shares.

Cogent Biosciences Inc (COGT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cogent Biosciences Inc Insider Transactions

No Available Data

Venrock Healthcare Capital Partners Iii, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Venrock Healthcare Capital Partners Iii, L.p.. You might contact Venrock Healthcare Capital Partners Iii, L.p. via mailing address: 530 Fifth Avenue, 22nd Floor, New York Ny 10036.

Discussions on Venrock Healthcare Capital Partners Iii, L.p.

No discussions yet.